Intuitive Surgical (NASDAQ:ISRG) PT Raised to $425.00

Intuitive Surgical (NASDAQ:ISRG) had its target price hoisted by equities researchers at Evercore ISI from $385.00 to $425.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “in-line” rating on the medical equipment provider’s stock. Evercore ISI’s price target would suggest a potential downside of 2.26% from the company’s current price.

Several other research firms also recently issued reports on ISRG. Robert W. Baird decreased their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research note on Friday, April 19th. Stifel Nicolaus raised their price target on Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. The Goldman Sachs Group initiated coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. BTIG Research raised their target price on shares of Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a research report on Friday, April 19th. Finally, Jefferies Financial Group lifted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $404.79.

Intuitive Surgical Stock Down 0.9 %

ISRG stock opened at $434.81 on Tuesday. The business has a 50 day moving average price of $406.41 and a 200 day moving average price of $385.08. The stock has a market cap of $154.23 billion, a price-to-earnings ratio of 78.49, a PEG ratio of 5.75 and a beta of 1.39. Intuitive Surgical has a fifty-two week low of $254.85 and a fifty-two week high of $448.10.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.00 EPS. As a group, sell-side analysts anticipate that Intuitive Surgical will post 4.8 EPS for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the transaction, the executive vice president now owns 5,507 shares in the company, valued at $2,037,149.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 1,498 shares of the company’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at $2,037,149.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Myriam Curet sold 5,318 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the completion of the transaction, the executive vice president now directly owns 298 shares of the company’s stock, valued at $110,456.68. The disclosure for this sale can be found here. Insiders have sold a total of 17,956 shares of company stock worth $6,927,011 over the last three months. 0.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Intuitive Surgical

Several large investors have recently bought and sold shares of the company. AQR Capital Management LLC increased its holdings in Intuitive Surgical by 0.8% during the 3rd quarter. AQR Capital Management LLC now owns 80,283 shares of the medical equipment provider’s stock valued at $23,466,000 after acquiring an additional 628 shares in the last quarter. Advisors Asset Management Inc. raised its position in shares of Intuitive Surgical by 2.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 7,649 shares of the medical equipment provider’s stock worth $2,236,000 after purchasing an additional 205 shares during the last quarter. Alps Advisors Inc. grew its holdings in Intuitive Surgical by 28.5% during the 3rd quarter. Alps Advisors Inc. now owns 4,555 shares of the medical equipment provider’s stock valued at $1,331,000 after buying an additional 1,010 shares during the last quarter. Seven Eight Capital LP increased its position in Intuitive Surgical by 3,634.2% during the third quarter. Seven Eight Capital LP now owns 36,371 shares of the medical equipment provider’s stock worth $10,631,000 after buying an additional 35,397 shares in the last quarter. Finally, Schroder Investment Management Group raised its holdings in shares of Intuitive Surgical by 25.2% in the third quarter. Schroder Investment Management Group now owns 95,481 shares of the medical equipment provider’s stock worth $27,908,000 after acquiring an additional 19,216 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.